Senescent cells: an emerging target for diseases of ageing

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Related collections

Most cited references 140

Record: found
Abstract: found
Article: found

Aging, Cellular Senescence, and Cancer

Judith Campisi (2013)

For most species, aging promotes a host of degenerative pathologies that are characterized by debilitating losses of tissue or cellular function. However, especially among vertebrates, aging also promotes hyperplastic pathologies, the most deadly of which is cancer. In contrast to the loss of function that characterizes degenerating cells and tissues, malignant (cancerous) cells must acquire new (albeit aberrant) functions that allow them to develop into a lethal tumor. This review discusses the idea that, despite seemingly opposite characteristics, the degenerative and hyperplastic pathologies of aging are at least partly linked by a common biological phenomenon: a cellular stress response known as cellular senescence. The senescence response is widely recognized as a potent tumor suppressive mechanism. However, recent evidence strengthens the idea that it also drives both degenerative and hyperplastic pathologies, most likely by promoting chronic inflammation. Thus, the senescence response may be the result of antagonistically pleiotropic gene action.

0 comments Cited 1086 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Cellular senescence in aging and age-related disease: from mechanisms to therapy.

Bennett Childs, Matej Durik, Darren J. Baker … (2015)

Cellular senescence, a process that imposes permanent proliferative arrest on cells in response to various stressors, has emerged as a potentially important contributor to aging and age-related disease, and it is an attractive target for therapeutic exploitation. A wealth of information about senescence in cultured cells has been acquired over the past half century; however, senescence in living organisms is poorly understood, largely because of technical limitations relating to the identification and characterization of senescent cells in tissues and organs. Furthermore, newly recognized beneficial signaling functions of senescence suggest that indiscriminately targeting senescent cells or modulating their secretome for anti-aging therapy may have negative consequences. Here we discuss current progress and challenges in understanding the stressors that induce senescence in vivo, the cell types that are prone to senesce, and the autocrine and paracrine properties of senescent cells in the contexts of aging and age-related diseases as well as disease therapy.

0 comments Cited 839 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Is Open Access

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

Yi-Yi Zhu, Tamara Tchkonia, Tamar Pirtskhalava … (2015)

The healthspan of mice is enhanced by killing senescent cells using a transgenic suicide gene. Achieving the same using small molecules would have a tremendous impact on quality of life and the burden of age-related chronic diseases. Here, we describe the rationale for identification and validation of a new class of drugs termed senolytics, which selectively kill senescent cells. By transcript analysis, we discovered increased expression of pro-survival networks in senescent cells, consistent with their established resistance to apoptosis. Using siRNA to silence expression of key nodes of this network, including ephrins (EFNB1 or 3), PI3Kδ, p21, BCL-xL, or plasminogen-activated inhibitor-2, killed senescent cells, but not proliferating or quiescent, differentiated cells. Drugs targeting these same factors selectively killed senescent cells. Dasatinib eliminated senescent human fat cell progenitors, while quercetin was more effective against senescent human endothelial cells and mouse BM-MSCs. The combination of dasatinib and quercetin was effective in eliminating senescent MEFs. In vivo, this combination reduced senescent cell burden in chronologically aged, radiation-exposed, and progeroid Ercc1 −/Δ mice. In old mice, cardiac function and carotid vascular reactivity were improved 5 days after a single dose. Following irradiation of one limb in mice, a single dose led to improved exercise capacity for at least 7 months following drug treatment. Periodic drug administration extended healthspan in Ercc1 −/Δ mice, delaying age-related symptoms and pathology, osteoporosis, and loss of intervertebral disk proteoglycans. These results demonstrate the feasibility of selectively ablating senescent cells and the efficacy of senolytics for alleviating symptoms of frailty and extending healthspan.

0 comments Cited 823 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Title: Nature Reviews Drug Discovery

Abbreviated Title: Nat Rev Drug Discov

Publisher: Springer Nature

ISSN (Print): 1474-1776

ISSN (Electronic): 1474-1784

Publication date Created: July 21 2017

Publication date (Print): July 21 2017

Volume:

Issue:

Article

DOI: 10.1038/nrd.2017.116

PMC ID: 5942225

PubMed ID: 28729727

SO-VID: 0e857c9d-d9df-44eb-b999-fe1a69a4b328

History

Data availability:

Comments

Comment on this article

scite_

Cited by 429

See all cited by

Most referenced authors 4,183

See all reference authors

- Version 1

Senescent cells: an emerging target for diseases of ageing

Read this article at

Abstract

Related collections

Genes & Diseases

Most cited references 140

Aging, Cellular Senescence, and Cancer

Cellular senescence in aging and age-related disease: from mechanisms to therapy.

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

Author and article information

Journal

Article

History

Comments

Comment on this article

Similar content 3,225

Cited by 429

Most referenced authors 4,183